BR112018000698A2 - composto de pirimidina condensado ou sal do mesmo - Google Patents

composto de pirimidina condensado ou sal do mesmo

Info

Publication number
BR112018000698A2
BR112018000698A2 BR112018000698-0A BR112018000698A BR112018000698A2 BR 112018000698 A2 BR112018000698 A2 BR 112018000698A2 BR 112018000698 A BR112018000698 A BR 112018000698A BR 112018000698 A2 BR112018000698 A2 BR 112018000698A2
Authority
BR
Brazil
Prior art keywords
salt
ret
compound
pyrimidine compound
condensed pyrimidine
Prior art date
Application number
BR112018000698-0A
Other languages
English (en)
Japanese (ja)
Other versions
BR112018000698B1 (pt
Inventor
Miyazaki Isao
Shimamura Tadashi
Kato Masanori
Fujita Hidenori
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of BR112018000698A2 publication Critical patent/BR112018000698A2/pt
Publication of BR112018000698B1 publication Critical patent/BR112018000698B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

o propósito da presente invenção é fornecer um novo inibidor de ret e um agente profilático ou terapêutico para doenças que podem ser prevenidas ou tratadas com o auxílio de uma atividade de inibição de ret (por exemplo, tumores malignos) cada um dos quais contém, como um ingrediente ativo, um composto que não é até agora conhecido ter uma atividade de inibição de ret ou um sal do composto. um inibidor de ret contendo, como um ingrediente ativo, um composto representado pela fórmula (i) [em que a, r1 a r3, x e n são como definido na descrição] ou um sal do mesmo.
BR112018000698-0A 2015-09-08 2016-09-07 Inibidores de ret, seus usos, composições farmacêuticas e agente antitumor BR112018000698B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-177073 2015-09-08
JP2015177073 2015-09-08
PCT/JP2016/076354 WO2017043550A1 (ja) 2015-09-08 2016-09-07 縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
BR112018000698A2 true BR112018000698A2 (pt) 2018-09-18
BR112018000698B1 BR112018000698B1 (pt) 2023-07-18

Family

ID=

Also Published As

Publication number Publication date
EP3260454A4 (en) 2018-02-21
US20190092776A1 (en) 2019-03-28
AU2016319525A1 (en) 2018-01-25
CN108026101A (zh) 2018-05-11
CA2996682A1 (en) 2017-03-16
PL3260454T3 (pl) 2021-11-22
RU2018112252A3 (pt) 2019-10-09
PH12017502407B1 (en) 2018-06-25
IL257306A (en) 2018-03-29
PH12017502407A1 (en) 2018-06-25
SG11201800135WA (en) 2018-02-27
MA41559A (fr) 2017-12-26
JP6113379B1 (ja) 2017-04-12
MX2018002889A (es) 2018-06-18
US11236096B2 (en) 2022-02-01
CA2996682C (en) 2021-01-12
WO2017043550A1 (ja) 2017-03-16
EP3260454A1 (en) 2017-12-27
IL257306B (en) 2021-07-29
US20200270260A1 (en) 2020-08-27
AU2016319525C1 (en) 2019-07-25
TW201716412A (zh) 2017-05-16
RU2729636C2 (ru) 2020-08-11
ES2877537T3 (es) 2021-11-17
RU2018112252A (ru) 2019-10-09
TWI675840B (zh) 2019-11-01
HK1254983A1 (zh) 2019-08-02
NZ739893A (en) 2019-07-26
KR102058366B1 (ko) 2019-12-23
US20180009817A1 (en) 2018-01-11
EP3260454B1 (en) 2021-06-09
CN108026101B (zh) 2020-06-26
US10233189B2 (en) 2019-03-19
JPWO2017043550A1 (ja) 2017-09-07
AU2016319525B2 (en) 2019-01-31
MY192184A (en) 2022-08-05
US20200270261A1 (en) 2020-08-27
US11014930B2 (en) 2021-05-25
US10787457B2 (en) 2020-09-29
ZA201800218B (en) 2019-06-26
KR20180042368A (ko) 2018-04-25

Similar Documents

Publication Publication Date Title
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015032595A2 (pt) inibidores de ido
BR112018016724A2 (pt) composto de pirimidina condensado ou sal do mesmo
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112015020650A2 (pt) inibidores de histona demetilases
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2016, OBSERVADAS AS CONDICOES LEGAIS